Compound monograph
Mazdutide
Mazdutide is a lipidated synthetic peptide classified as a GLP-1 and glucagon receptor dual agonist, built on an oxyntomodulin-derived backbone.
01
Identity & nomenclature
Mazdutide is a lipidated synthetic peptide classified as a GLP-1 and glucagon receptor dual agonist, built on an oxyntomodulin-derived backbone.
The formula recorded here is the WHO-defined structure. PubChem's name-linked record reports C207H317N45O65, which differs by exactly one serine residue — C3H5NO2, 87.0320 Da. That is a difference in covalent peptide composition, not a salt form or a protonation state. PubChem CID 172871914 encodes the specified 34-residue peptide ending GGPSSG-NH2 with Aib2 and the Lys20-linked two-AEEA, gamma-L-glutamyl, C20-diacid modification, whereas CID 167312357 lacks one terminal-region serine. The discrepancy is evidence of a database conflict; it is not evidence about what any particular sample contains. Text extracted from WHO Proposed INN List 126 and Recommended List 88 gives Asp at position 9 in English, French and Spanish, but one indexed copy of List 88 gives Lys in French and Spanish; this record keeps Asp9, which its printed sequence also shows.
Declared aliases and development codes: IBI362, IBI-362, LY3305677, LY-3305677, IBI362, LY3305677.
02
Molecular properties
| Molecular formula | C210H322N46O67 |
|---|---|
| Molecular mass | 4563.07 Da |
| CAS Registry Number | 2259884-03-0 |
| PubChem CID | 172871914 |
| UNII | MB76Z4IBZ5 |
| Three-letter sequence | His–Aib–Gln–Gly–Thr–Phe–Thr–Ser–Asp–Tyr–Ser–Lys–Tyr–Leu–Asp–Glu–Lys–Lys–Ala–Lys–Glu–Phe–Val–Glu–Trp–Leu–Leu–Glu–Gly–Gly–Pro–Ser–Ser–Gly |
| Terminal groups | Free N-terminus; C-terminal amide at Gly34 |
Thirty-four residues ending Gly-Gly-Pro-Ser-Ser-Gly with a C-terminal amide. BOTH serines near the C-terminus belong in the sequence; a species missing one would be 87.0320 Da lighter. Position 2 is Aib, 2-aminoisobutyric acid — not Ac4c, which is what survodutide carries. Lys20 is acylated through two AEEA spacers, a gamma-L-glutamyl unit and a C20 dicarboxylic fatty acid.
03
Structural characteristics
Described in its literature as an oxyntomodulin analog. The related oxyntomodulin entry identifies the stated structural parent; no direct derivation from mature glucagon is claimed here. GLP-1(7-36) amide is a native receptor comparator, not a structural parent. Position 2 is alpha-aminoisobutyric acid, not the Ac4c of survodutide, and lipidation uses two AEEA spacers from the lysine 20 side chain. Survodutide and mazdutide share a receptor profile and are not chemically interchangeable. The dual-receptor classification is supported at the target-class level. What is NOT established in the verified source set, and is stated here rather than filled in: a quantitative receptor potency ratio for this compound, matched binding affinities, full-versus-partial agonist classification under defined conditions, and signalling-bias parameters. Every reference in this entry is Class B — none is a mazdutide-bound structure or a mazdutide-specific receptor pharmacology study. Findings from comparator dual agonists describe those comparators. Being oxyntomodulin-derived is not permission to substitute oxyntomodulin's sequence or another dual agonist's data.
- Aib at position 2
- Lys20 acylation via two AEEA spacers and gamma-Glu
- C20 dicarboxylic fatty-acid acylation
Terminal features: Free N-terminus, C-terminal amide at Gly34.
04
Molecular targets & mechanisms
Glucagon-like peptide-1 receptor
GLP-1R
GLP-1R is a class B G-protein-coupled receptor. The cited structural and pharmacology records characterize semaglutide and retatrutide as peptide agonists at this receptor.
Glucagon receptor
GCGR
GCGR is a class B G-protein-coupled receptor. Retatrutide's LY3437943 discovery record characterizes a molecular agonist relationship at GCGR alongside GIPR and GLP-1R.
05
Analytical considerations
The first identity question is whether a sample matches the WHO-defined composition rather than the mass attached to a name-matched database record. Tandem MS should establish the C-terminal Pro-Ser-Ser-Gly segment and verify both serines independently; a species short one serine is 87.0320 Da lighter, which intact mass can flag but only fragmentation can localise. The remaining features are Aib2, Lys20 conjugation, TWO AEEA spacers, gamma-Glu connectivity, the C20 diacid and the Gly34 amide. A correct intact mass without branch mapping does not exclude a linker-connectivity isomer. GSRS UNII MB76Z4IBZ5 describes the matching sequence and modifications but reports C210H328N46O69 and an estimated 3790.0 Da, conflicting with the structure represented by PubChem CID 172871914. A certificate reporting only HPLC purity and an approximate 4.5 kDa mass does not resolve the database conflict above.
Disagreements and mix-ups
Points where sources disagree about this compound's identity, or where a name or form is easily confused with another, as noted in this record. The discrepancy register quotes the passage for each one.
Sources disagree · this Library follows one source · Formula or mass
One serine more or fewer between two registry structuresSources disagree · this Library follows one source · Notation
Mazdutide's position 9 in copies of the WHO listsOften mixed up · Name or substance
Survodutide vs mazdutideAlso noted in Survodutide
Often mixed up · Notation
Ac4c vs Aib at position 2Also noted in Survodutide
Often mixed up · Name or substance
Glucagon-derived vs oxyntomodulin-derivedAlso noted in Survodutide, Oxyntomodulin
What the studies reported
No verified findings are published for this record under Content Policy v1.
06
Verified bibliography
Cited studies by type
The 4 papers this record cites, counted by the kind of work each reports. A count is the size of this record's selection, not of the research that exists, and says nothing about results, safety, effectiveness or approval.
A paper can report more than one kind of work. Each count opens those papers in the bibliography. Compare every record on the Evidence Map.
Reference 1
Structural analysis of the dual agonism at GLP-1R and GCGR.Li Y, Zhou Q, Dai A, Zhao F, Chang R, Ying T, Wu B, Yang D, Wang MW, Cong Z
Proceedings of the National Academy of Sciences of the United States of America · 2023-08-07 · Journal Article
currentReference 2
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.Darbalaei S, Yuliantie E, Dai A, Chang R, Zhao P, Yang D, Wang MW, Sexton PM, Wootten D
Biochemical pharmacology · 2020-07-17 · Journal Article
currentReference 3
Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.Pickford P, Lucey M, Rujan RM, McGlone ER, Bitsi S, Ashford FB, Corrêa IR, Hodson DJ, Tomas A, Deganutti G, Reynolds CA, Owen BM, Tan TM, Minnion J, Jones B, Bloom SR
Molecular metabolism · 2021-04-30 · Journal Article
currentReference 4
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, Haupt A, Thomas MK, Tham LS, Calderon B, Ni W, De Araujo OFG
The lancet. Diabetes & endocrinology · 2026-08-21 · Journal Article
current
Study models of these references
What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.
| Reference | Study models |
|---|---|
| Li Y et al. 2023 | Study models reported: in vitro · from the abstract |
| Darbalaei S et al. 2020 | Study models reported: in vitro · from the abstract |
| Pickford P et al. 2021 | Study models reported: in vitro; animal (mouse) · from the abstract |
| Hsia SH et al. 2026 | Study models reported: human participants (interventional) · from the abstract |
Compare
Record history
Published 2026-09-13.
- : References
- : Sequence and structure
- : Identity and nomenclature, Analytical notes
- : Identity and nomenclature, Sequence and structure
- : Sequence and structure
Each entry names the parts of this record that changed on that date. Changes to links between records and to catalogue links are not listed. This history covers the tracked record fields; study findings are not listed here.
Cite this record: Purely Peptides Research Library. Mazdutide. Published 2026-09-13; updated 2026-10-16. https://purelypeptides.org/research/compounds/mazdutide/
10
Methodology & citation verification
Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.
Read the full methodology →